Copaxone Legal Fight May Finally Be Over As Court Finds The MS Treatment Is Not A Biologic

US FDA’s interpretation of ‘protein’ is reasonable and owed deference, the court concludes in tossing Teva suit which challenged Copaxone’s exclusion from list of drugs transitioned to being regulated as biologics.

Courthouse Pillars & Stairs
District court dismisses Teva's suit against FDA over Copaxone designation • Source: Shutterstock

The long saga of Teva Pharmaceuticals USA Inc.’s fight to block additional Copaxone competitors from entering the market appears to have come to an end with a district court ruling that the US Food and Drug Administration reasonably determined that the multiple sclerosis treatment is not a biologic.

Teva filed suit against FDA last year challenging its decision to exclude Copaxone (glatiramer acetate injection) from a list of...

More from Legal & IP

More from Pink Sheet